SCHEMBL2344472

SCHEMBL2344472

Cn1nc(-c2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)ccc1=O

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 0.54
CYP2D6 P10635 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12449929 0.85 HRH3 (0.46) HRH3CYP2D6KCNH2
SCHEMBL12450005 0.85 HRH3 (0.50) HRH3KCNH2
SCHEMBL2341193 0.81 HRH3 (0.53) HRH3CYP2D6KCNH2
SCHEMBL1639543 0.80 HRH3 (0.61) HRH3CYP2D6
SCHEMBL12748456 0.79 HRH3 (0.52) HRH3CYP2D6KCNH2
SCHEMBL1638987 0.78 HRH3 (0.64) HRH3CYP2D6KCNH2
SCHEMBL12828008 0.78 HRH3 (0.55) HRH3CYP2D6KCNH2
SCHEMBL11918482 0.77 HRH3 (0.57) HRH3CYP2D6KCNH2
SCHEMBL12749370 0.76 HRH3 (0.52) HRH3CYP2D6KCNH2
SCHEMBL2341776 0.76 HRH3 (0.56) HRH3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310389-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2013-11-21 US disclosed
US-8524713-B2 Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC (US) 2013-09-03 US disclosed
US-8524713-B2 Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC (US) 2013-09-03 US disclosed
EP-2257553-B1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON INC (US) 2011-08-31 EP disclosed
EP-2257553-B1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON INC (US) 2011-08-31 EP disclosed
US-20100298332-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2010-11-25 US disclosed
US-20100298332-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2010-11-25 US disclosed
WO-2009097309-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298332-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands HRH3, HRH4, HRH2 HRH3 1/4885CYP2D6 1437/4885KCNH2 336/4885
US-20130310389-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS HRH3, HRH4, HRH2 HRH3 1/4885CYP2D6 1369/4885KCNH2 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.